Suppr超能文献

运动铊-201心肌闪烁扫描正常的患者:预后总是良好吗?

Patients with a normal exercise thallium-201 myocardial scintigram: always a good prognosis?

作者信息

Oosterhuis W P, Breeman A, Niemeyer M G, Zwinderman A H, Kuijper A F, van der Wall E E, Tijssen J G, Pauwels E K

机构信息

Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.

出版信息

Eur J Nucl Med. 1993 Feb;20(2):151-8. doi: 10.1007/BF00168876.

Abstract

The prognostic value of a normal exercise thallium-201 scintigram was determined in 211 patients with a normal exercise and resting scintigram. Endpoints were sudden cardiac death, non-fatal acute myocardial infarction and coronary artery bypass grafting or percutaneous transluminal coronary angioplasty. Forty patients (19%) had a history of a previous myocardial infarction and 40 (19%) were known to have had a previous percutaneous transluminal coronary angioplasty or coronary artery bypass grafting. Sixty-four patients (31%) were on treatment with beta-blocking agents. After a mean follow-up period of 23.5 months, 22 patients had had a cardiac event (1 cardiac death, 6 myocardial infarction, 15 revascularization). For the total group, the 1-year event rate for cardiac death, myocardial infarction, percutaneous transluminal coronary angioplasty or coronary artery bypass grafting was 7.0%. For cardiac death or myocardial infarction alone the event rate was 2.8%. The only parameter independently predictive for cardiac events was the regular use of beta-blocking agents. The high event rate in patients on beta-blocking treatment is partly due to the fact that these patients were more symptomatic for coronary artery disease. The sustained beta-adrenergic blockade in this patient group, even in patients advised to stop medication, was suspected to interfere with the results of 201Tl scintigraphy. Therefore, more attention should be paid to patient instruction regarding the discontinuation of medication before the test.

摘要

对211例运动和静息心肌闪烁显像均正常的患者,测定了正常运动铊-201闪烁显像的预后价值。观察终点为心源性猝死、非致死性急性心肌梗死以及冠状动脉旁路移植术或经皮腔内冠状动脉成形术。40例患者(19%)有既往心肌梗死病史,40例(19%)已知曾接受过经皮腔内冠状动脉成形术或冠状动脉旁路移植术。64例患者(31%)正在接受β受体阻滞剂治疗。平均随访23.5个月后,22例患者发生了心脏事件(1例心源性死亡、6例心肌梗死、15例血运重建)。对于整个研究组,心源性死亡、心肌梗死、经皮腔内冠状动脉成形术或冠状动脉旁路移植术的1年事件发生率为7.0%。仅心源性死亡或心肌梗死的事件发生率为2.8%。唯一独立预测心脏事件的参数是β受体阻滞剂的常规使用。接受β受体阻滞剂治疗的患者事件发生率较高,部分原因是这些患者冠心病症状更明显。怀疑该患者组持续的β肾上腺素能阻滞,即使是建议停药的患者,也会干扰铊-201闪烁显像的结果。因此,在检查前应更加重视对患者停药的指导。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验